In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May

Fill out this form for personalized 1:1 nutrition counseling and learn how to: Lose weight safely on GLP-1 medications Support your bodys natural satiety hormones Protect lean muscle and metabolism Prevent hair loss and maintain energy Build a sustainable nutrition plan that works for your lifestyle This blog was written in partnership with StarKist, but all opinions are own.
[2] It might sound like a hassle, but for those comparing a semaglutide pill vs injection, a few extra minutes in the morning is a small price to pay for ditching the needle
Welcome aboard, Hong Kong (HK) and the United Arab Emirates (UAE)
But after I had a burst of energy
Laboratory markers include suppressed free T3 with normal TSH (euthyroid sick syndrome), elevated cortisol, and in severe cases, low LH and FSH indicating hypothalamic suppression